CSPHP Kyowa SuperSoy is a newly developed soy peptide that significantly decreases serum concentrations of total cholesterol and LDL cholesterol. It was made by fortifying soy's widely known serum-cholesterol reducing property by binding enzymatic-decomposed lecithin to hydrolyzed isolated soy protein in the ration of 80/20 (wt/wt). The two components are considered to be bonded in a hydrophobic manner.
Cross-over tests, using male Wistar rats, indicated that SPHP [fractionated CSPHP] produced the effects of both reducing high cholesterol levels and suppressing cholesterol increases induced by a high cholesterol diet. The rats were divided into two groups and fed diets that contained either casein or SPHP (20% wt/wt, in addition to 0.5% cholesterol diet) for the first 10 days. The SPHP-fed group significantly suppressed the serum cholesterol elevation. After exchanging the diets of the two groups, the elevated level of the former casein-fed group decreased dramatically and returned to the normal level as a result of the SPHP diet.
CSPHP is useful in humans for its ability to normalize the high cholesterol level of hypercholesterolemic patients and also for maintaining serum cholesterol level when ingesting high cholesterol meals. Taking 3 or more grams of CSPHP per day for 3 consecutive months, reduced both the total cholesterol and LDL-cholesterol level of hypercholesterolemic patients (265±6.9mg/dl). Both cholesterol levels showed a decrease at the end of a 1 month period of 10.4% and 17.1% (vs. initial), respectively. The maximum reduction for each level was 15% and 27.7% (p<0.05), respectively, at the end of a 3 month period. Oral CSPHP of 3g significantly suppressed the serum total and LDL-cholesterol surge when given to healthy humans (167±7.7mg/dl) receiving a high cholesterol diet (2 egg yolks/day).
- Goro Hori, Yoichiro Sugimura, Kazuhiro Yamamoto, Tsunemi Haraguchi, Kohei Yamamoto, Satoshi Nagaoka and Shigeru Yamamoto